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At a false-positive rate (FPR) of 5%, specificity for R5-tropic virus was also high
(range: 85.7%-95.3%), but came at the expense of sensitivity for X4-using virus
(range: 36.7%-66.7%). One study compared the effectiveness of both genotypic tro-
pism testing and ESTA in predicting virological response to the CCR5-antagonist
maraviroc. The study found in each screening group, a similar proportion of pa-
tients achieved a viral load 50 HIV-1 RNA copies/mL byWeek 48. CONCLUSIONS:
In the absence of a ‘gold standard’, clinical response to CCR5-anatagonist therapy offers
the bestmeasure of diagnostic performance in HIV-1 tropism testing. The results of this
review indicate that genotypic sequencing of the V3 loop is as capable of predicting re-
sponse toCCR5-antagonist therapyas the currentdiagnostic standard, ESTA. Inaddition,
of the bioinformatic algorithms reviewed here, the geno2pheno model set at 5-10% FPR
offered the best balance between sensitivity and specificity. This evidence provides fur-
ther support for the use of genotypic tropism testing in routine clinical practice.
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OBJECTIVES: To evaluate the relationship between vancomycin trough concentra-
tion and the clinical outcome in hospitalized patients with ORSA bacteremia, and
to assess the relationship between vancomycin trough concentration and
nephrotoxicity. METHODS: Adult patients admitted to National Cheng-Kung Uni-
versity Hospital during January 20, 2006 and July 31, 2006 and treated with vanco-
mycin for ORSA bacteremia were eligible for this prospective observational study.
On the fourth day after vancomycin use, vancomycin concentration was moni-
tored and blood culture was repeated. Regular biochemistry and blood test on day
4, 7, 11, 14, daily highest temperatue and other associated data were collected. The
primary endpoints are the clinical outcome and the change of serum creatinine
concentration. RESULTS: Nineteen patients were enrolled during this period. On
day 4, trough concentration of vancomycin was associated with the rate of defer-
vescence. The afebrile rate were 85.7% and 33.3% among patients with trough level
of above and below 15 g/mL, respectively (P  0.05). For the ratio of vancomycin
trough concentration to MIC, patients with ratio greater than 10 had a trend of a
higher defervescence rate in comparison with those with ratio less than 10 (77.8%
vs. 30%, P  0.07). In addition, nephrotoxicity was found in five patients, but the
mean trough concentrations were not significantly different between the nephro-
toxic and non-nephrotoxic groups. CONCLUSIONS: The result of the study shows
that higher serum vancomycin trough concentration is associated with the defer-
vescence rate on day 4 when vancomycin is used to treat ORSA bacteremia. Be-
sides, under the condition of regular therapeutic drug monitoring, the nephrotox-
icity during vancomycin therapy doesn’t seem to be associated with trough
concentration, but it needs studies with large sample size to evaluate.
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OBJECTIVES: Large antimicrobial consumption in intensive care units (ICUs) con-
tributes heavy health care burden in Taiwan. This study evaluates the short term
influence of pharmacist-led antimicrobial stewardship (PLAS) in ICUs.METHODS:
A prospective PLAS program was implemented in medical and surgical ICUs, in-
cluding dose optimization (renal dose monitoring and therapeutic drug monitor-
ing), streamlining or de-escalation of therapy, antimicrobial order forms, and an-
timicrobial treatment duration review, which any antimicrobial duration over
7days was reviewed. Data collection was from October 19, 2011 to December 2,
2011. Patients who admitted to ICU and received at least one parenteral antimicro-
bial were included. Outcomes included suggestion implementation rate of phar-
macist interventions and cost that saving from dose optimization. Feedbacks of
non-accepted suggestions were also addressed. RESULTS: Sixty-two (21%) of study
population received 88 suggestions. Sixty-two (70.5%) suggestions were imple-
mented. Themajority of suggestions is duration review (30.7%) followed by stream-
lining or de-escalation of therapy (30.6%) and dose optimization (27.3%). There was
76,238 NTDs saving from renal dose monitoring. Further efforts we can make are
found from reasons of non-accepted suggestion. For example, education on pro-
phylactic antibiotics and antimicrobial renal dosage adjustment should be
provided. Since, we found that prolonged (3days) post-operation antimicrobial
prophylaxis until inserted drainage lumen removed and refusing dose increasing
because impaired renal function was expected by doctors. Involvement in multi-
disciplinary specialists is required due to denials from no recommendation from
infectious disease physicians. CONCLUSIONS: A PLAS efforts rationale antimicro-
bial utilization and leads to potential reduction in both the incidence of adverse
effects and the burden of health care. Through feedback from refused suggestion,
however, we found that antimicrobial stewardship should include a multidisci-
plinary team, especially incorporating with infectious disease physicians.
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OBJECTIVES: The optimal timing of initiation of Antiretroviral Therapy (ART) in
ART naïve patients with HIV and TB co-infection remains inconclusive. IRIS inci-
dence is one of the most important outcomes that we need to consider when
making a decision on the time of initiating ART. This study compared the IRIS
incidence in patients initiating ART earlier (2 months after the start of tubercu-
losis therapy) versus later (2 months after the start of tuberculosis therapy). We
also examined the differences of IRIS incidence between early and late arms in the
Resources limited settings (RLS) and the Non Resources limited settings (NRLS).
METHODS:Data for this meta-analysis were extracted from Pubmed/Medline, Em-
base, Cochrane database of systematic review, Cochrane Central Register of Con-
trolled Trials, International Pharmaceutical Abstracts, ClinicalTrials.gov and
Google Scholar from year 1986 to 2011. We searched by using a combination of
terms: HIV, HIV infections, acquired immunodeficiency syndrome, tuberculosis,
TB, HAART, highly active antiretroviral therapy, ART, antiretroviral therapy. Out of
the 11300 studies found in the search, five cohort studiesmet the inclusion criteria.
Among the five studies, two were located in RLS and three were located in NRLS.
We conducted a meta-analysis of these five studies by using STATA SE version 12.
RESULTS:Meta-analysis results showed that overall, people treated with ART ear-
lier during TB therapy had a 12.9% lower risk of IRIS incidence compared to people
treated later (RR, 0.871; 95% CI, 0.831-0.912). In addition, the differences of IRIS
incidence between early and late arms were significant in both the Resources lim-
ited settings (RLS) and the Non Resources limited settings (NRLS). CONCLUSIONS:
Initiating antiretroviral therapy less than 2 months after the start of tuberculosis
therapy is associated with a significantly lower risk of IRIS incidence, regardless of
the locations.
PIN6
JAPANESE ENCEPHALITIS IN ASIA: CLINICAL BURDEN AND COST-
EFFECTIVENESS OF VACCINATION PROGRAM
Wadhwa A1, Mann K1, Ahuja A2
1Heron Health Pvt. Ltd., Chandigarh, Chandigarh, India, 2HERON Health Pvt. Ltd.,
Chandigarh, Chandigarh, India
OBJECTIVES: To report clinical burden of Japanese encephalitis (JE) in Asia and
cost-effectiveness of JE vaccination program. METHODS: Systematic literature
searches were conducted using Embase®, MEDLINE®, WHO, and Google scholar
platforms to identify relevant studies in patients with JE. Eligibility of trials was
assessed by two reviewerswith any discrepancy reconciled by a third, independent
reviewer. RESULTS: A total of 10 studies out of 41 retrieved, met the inclusion
criteria for the clinical review. Approximately 35,000-50,000 JE cases and 10,000–
15,000 deaths due to JE were reported every year in Asia. Incidence of JE was high in
China and India, with China accounting for 50% of the JE cases reportedworldwide.
The incidence of JE in China was reported to be 0.01-1.53 residents/year/100,000.
The number of JE cases reported in China, India, Nepal, Sri Lanka, and Bangladesh
were 5,000-10,000, 1,500-4,000, 1,000-3,000, 100-200, and 56, respectively. JE caused
12,038 and 2,496 deaths in Southeast Asia andWestern Pacific, respectively (2008).
JE was associated with 491,797 disability-adjusted life years (DALYs) in the South-
east Asia and 185,573 DALYs in the Western Pacific region (2004). Four studies out
of 59 retrieved, met the eligibility criteria for evaluating cost-effectiveness of JE
vaccination. JE vaccination prevented 117 cases and 12 deaths (Vietnam), 103 cases
and 18 deaths (Thailand), 420 cases and 105 deaths (China), and 175-316 cases and
36-65 deaths (India). Total savings in the direct medical costs witnessed as a con-
sequence of JE vaccination were $51,122 (Vietnam), $58,776 (Thailand), $614,762
(China), and $178,558-$319,627 (India). CONCLUSIONS: JE has lead to significant
morbidity in survivors and mortality in Asian countries. Existing evidence from
cost-effectiveness studies demonstrated that vaccination program markedly re-
duced the burden of JE in Asia.
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OBJECTIVES: To assess the incidence and distribution of infectious diseases which
have been markedly affected by climate change. METHODS: Literature searches
were performed using Embase®, MEDLINE®, Google Scholar, and WHO website.
RESULTS: Current evidence suggests that inter-annual and inter-decadal climate
variability have a direct impact on the epidemiology of infectious diseases. Accord-
ing to WHO, since mid-1970s, climatic changes have caused annually over 150 000
deaths and an approximately 5 million disability-adjusted life-years, mainly in
developing countries. Malaria has been considered as an extremely climate-sensi-
tive disease. A temperature rise of 2°C-3°C increases the risk of malaria by 3%-5%.
Across the world, the incidence cases of malaria increased from 233 000 in 2000 to
244 000 in 2005, with highest incidence observed in Africa. The West Nile virus
(WNV) disease is considered as an emerging epidemic in the US. More than 7000
neuroinvasiveWNV disease cases were reported in the US from 1999-2004. Parallel
to rising temperatures, the US has recorded a 41% increase in vibrio infection rate
from 1996-2006. In continental Europe, a temperature rise of 6°C above the mean
resulted in an estimated 30% reported cases of salmonellosis. In Russia, rising
temperatures from 2001 have increased the incidence of tick-borne encephalitis
(TBE) by 10-fold within a decade. Korea’s climatic variability has also been posi-
tively correlatedwith the incidence cases ofmalaria, Vibrio vulnificus sepsis, scrub
typhus, leptospirosis, and Hantavirus infection during 2001-2008. Further, in 2009-
2010, government officials of Europe have predicted that borreliosis, WNV fever,
A666 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 6 0 2 – A 6 8 1
TBE, and salmonellosis are likely to be majorly affected by climate change.
CONCLUSIONS: Accelerating climate change carries a profound threat for the in-
creased burden of infectious diseases worldwide. To attain the maximum disease
prevention, an understanding of the ecology of infectious diseases must be devel-
oped in order to protect vulnerable populations, rather than focussing on single
agent of disease.
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OBJECTIVES: To forecast and better understand the primary drivers of the inci-
dence and prevalence of andmortality from drug sensitive andmultidrug resistant
tuberculosis (DS-TB and MDR-TB, respectively).METHODS: The Tuberculosis Sim-
ulation Model (TBSM) is a dynamic disease simulation model that uses historical
and current disease incidence, treatment success rates, mortality, and transmis-
sion trends and can account for expected market events to estimate future DS-TB
and MDR-TB incidence, prevalence and mortality in China. RESULTS: The model
shows that between 2010 and 2050, DS-TB incidence, prevalence andmortality will
decrease by 29%, 52% and 29%, respectively, whereas MDR-TB incidence, preva-
lence and mortality will fall by 3%, -11% and 10%, respectively. These reductions
would be driven by an expected decrease in the pool of people with latent infection
(brought about by improved cure rates which in turn reduces transmission rates)
and reduced rate of progression from latent to active TB. CONCLUSIONS: Results
from this model demonstrate considerable anticipated decreases in DS-TB and
MDR-TB incidence and mortality in China over the next forty years; the decreases
are much larger for DS-TB than for MDR-TB. Improvements in MDR-TB diagnosis
and improved cure rates due to betterMDR-TB treatments can likewise be expected
to decrease MDR-TB incidence, prevalence and mortality over the long run. This
adaptable TBSM tool has potential value in public health practice by forecasting
outcomes of interventions and can also be useful for cost effectivenessmodeling by
country or by region by defining critical unmet need.
INFECTION - Cost Studies
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OBJECTIVES: To compare direct health care costs of treatment experienced pa-
tients with HIV/AIDS before and after triple class failure across participating
centers.METHODS: The resource use data for eligible patients were collected two
years before, and  90 days following the date of triple class failure (TCF), which
was between January 2002 and June 2008. The treatment failure was defined as
virological failure to at least one drug from each of three classes (NRTI, NNRTI and
PI). Costs of resource use at patient levelwere estimated bymultiplying the number
of resources used by the national micro-costing-based estimates. Comparisons of
log-transformed expenditure data for the first 3, 6, 12 and 24 months before TCF
with their corresponding intervals after TCF were carried out using linear mixed
model. RESULTS:Of 42 patients recruited,mean agewas 38 years andmajority was
male (66.7%). Outpatient visit expenditure after TCF was significantly 78.767.34,
78.2613.28 and 683.0090.21 baht higher than that before TCF during the first 3, 6
and 24months respectively (P0.001,0.003, and0.001, respectively). Compared
with before TCF, expenditures on direct HIV lab tests (CD4/viral load/genotyping)
after TCF were significantly 5133.74661.80, 6907.23742.23, 7505.29981.76 and
9069.931219.37 Baht higher at the first 3, 6, 12 and 24 months, respectively
(P0.001, 0.001, 0.001, and 0.004, respectively). Expenditures on antiretroviral
medications after TCFwere also higher althoughwith significance only for the first
24 months (148414.0632322.67 baht higher, P0.007) and with borderline signifi-
cance for the first 3, 6 and 12months. Finally, overall direct expenditures after TCF
were significantly higher than those before TCF in all 4 periods. CONCLUSIONS:
Once triple class failure occurred, overall direct expenditures increased signifi-
cantly as early as 3 months and through 2 years of follow-up. The most dramatic
increase was the costs associated with laboratory tests, especially genotyping, and
outpatient visits.
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OBJECTIVES: Older adults are in an increasing risk of pneumococcal diseases, in-
cluding meningitis and bacteremia (invasive pneumococcal disease, IPD), and
pneumonia. The objective of this study was to estimate the clinical and economic
burden of pneumococcal disease in adults 50 years of age in Taiwan.METHODS:
Cases of hospitalized IPD and cases of hospitalized and outpatient pneumonia
were obtained by ICD-9 codes from Taiwan’s National Health Insurance Reim-
bursement Database from 2002-2009. Pneumococcal pneumonia was assumed to
comprise 23.8% of all-cause pneumonia based on published literature. Data were
stratified by age groups 50-64, 65-74, 75-84 and 85. Average incidence rates were
calculated by dividing cases by age group and year specific population figures. Cost
was extracted from the database for inpatient and outpatient cases; mortality es-
timation was based on hospital mortality. RESULTS: The average incidence per
100,000 person years was 2.4 for IPD, 278.8 for hospitalized pneumococcal pneu-
monia, and 1376.4 for outpatient pneumococcal pneumonia. Mortality was 12.2%
for IPD and 10.0% for hospitalized pneumonia. Comparedwith adults 50-64 years of
age, the incidence of pneumococcal hospitalization were 3.7 fold higher in those
65-74, 9.7 fold higher in 75-84 and 19.5 fold higher in those 85. The total number
of hospitalizations increased by 20% from 2002 to 2009, largely attributable to pop-
ulation growth. In 2009, there were 16,711 pneumococcal hospitalizations, 103,302
outpatient visits, and 1,920 deaths, with a total cost of NT$ 2.92 billion. Hospitalized
pneumococcal pneumonia was responsible for 94% of costs and 99% of mortality.
CONCLUSIONS: The morbidity and mortality of pneumococcal disease increases
sharply with advancing age, signaling an increasing public health problem in older
adults as the population ages. Expanded utilization of cost-effective treatment and
prevention efforts are warranted to alleviate the burden of pneumococcal diseases
in Taiwan.
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OBJECTIVES: To estimate direct medical cost and productivity lost for invasive
pneumococcal diseases in child under 2 in urban China. METHODS: Six health
status contained pneumococcal meningitis (inpatient), pneumococcal septicemia
(inpatient), pneumonia (all-cause, inpatient), pneumonia (all-cause, outpatient),
mild otitis media (all-cause,outpatient) and sever otitis media (all-cause, outpa-
tient )were considered. Age-specific cost was collected from electronic patient re-
cords (2010) from 14 hospitals in 7 cities in China. 2 hospitals in each city was
selected (1 Children’s Hospital, 1 Comprehensive Hospitals) and 7 field cities in-
cluding Beijing, Guangzhou, Shenzhen, Wuhan, Xi’an, Chengdu and Shenyang
were enrolled. Directmedical cost included registry fee, medications, and diagnos-
tic tests fee, hospitalization expenditure. Cost of productivity lost were days for
work absent of patient plus time consumed of infirmaries. In first part, weighted
average method was used to calculate average direct medical cost. In second part,
daily wage rate was applied to estimate cost of productivity lost. RESULTS: The
average direct medical cost in all IPD cases (pneumococcal meningitis& pneumo-
coccal septicemia) was 20,950 Yuan (95%CI: 4,489-101,003). Average 19 working
days lost in patients’ relatives for caring and costs of productivity lost was 1934
Yuan (95%CI: 532-6,412) per patient. CONCLUSIONS: IPD has a serious impact on
life quality of child under 2 in Chinese urban areas and it could lead to severe
economic burden.
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OBJECTIVES: To analyze the inpatient direct medical costs of pneumonia among
regions, level of cities, and types of the hospitals. Difference of reimbursement rate
between the Urban Employee Basic Medical Insurance (UEBMI) and Urban Resident
Basic Medical Insurance (URBMI) plans were compared. METHODS: Systematic
sampling was used to collect data on inpatients costs of pneumonia in 2009 in
China. The database includes 2868 hospitals from 60 cities. Direct medical costs of
inpatients with pneumonia and reimbursement rate between UEBMI and URBMI
planswere analyzed. RESULTS: In 2009, pneumonia was themost frequent disease
in children below 5 years old and 5th among people 6 to 65 years old in China. In
total 210,421 hospitalization case, the average cost of inpatient pneumonia was
5,415 Yuan ($853) per patient, and the expense in capital cities, prefectural-level
cities, and county-level cities were 16,375 Yuan ($2,579), 4,321 Yuan ($681), and
4,434 Yuan ($698), respectively. The average length of hospitalizationwas 14.6 days
for patients covered with UEMBI, and 11.7 days for those covered with URMBI.
Almost 67% of the direct medical costs were covered by two medical insurance
systems, but differed by system as 73.35% for urban employees and 51.99% for
urban residents. Patients below 5 years old paid 64.76% of the direct medical costs
out of pocket, whereas people over 65 year old only paid 27.2% because they were
shielded by two different systems. CONCLUSIONS: In China, pneumonia is a com-
mon disease that mainly affects children and elderly people. There was significant
difference in directmedical costs and the length of hospitalization among different
regions and medical insurance systems. Costs in big cities were much higher than
smaller ones because of the unbalanced distribution and uneven economics situ-
ation. The reimbursement rate of URMBI was much lower than that of UEMBI.
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COST OF ANTIBIOTICS USED FOR NOSOCROMAIAL INFECTION TREATMENT IN
INPATIENT DEPARTMENT AT NAKHON PATHOM HOSPITAL
Tewthanom K
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OBJECTIVES: Nosocomial infection can occur more frequently in patients on ad-
mission to the hospital. Patients must result in a longer treatment stays, and in-
crease costs from the use of antibiotics to treat patients. The purpose of this study
was aimed to calculate the value of antibiotics used to treat patients with nosoco-
mial infections in inpatient department at Nakhon Pathom hospital. METHODS:
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